Combinations of anti-IGF-1R antibodies or small molecule inhibitors of IGF-1R with gemcitabine, which are used widely to treat pancreatic cancer, have additive or synergistic effects on growth and survival [48, 49]. This evidence concerns the gene IGF1R and pancreatic neoplasm.